Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (NYSE: LYEL) is a clinical-stage biotechnology company developing novel T-cell therapies for solid tumors and hematologic malignancies through proprietary genetic/epigenetic reprogramming technologies. This page serves as the definitive source for verified company announcements, research breakthroughs, and regulatory developments.
Investors and researchers will find timely updates on Lyell's innovative pipeline including CAR T-cell candidates LYL797 and LYL119, tumor-infiltrating lymphocyte therapy LYL845, and dual-targeting IMPT-314 from the ImmPACT Bio acquisition. Our curated news collection covers essential developments across three key areas:
Clinical Trial Milestones: Phase 1/2 updates, patient enrollment progress, and safety/efficacy data disclosures
Research Innovations: Peer-reviewed study publications, ASCO/SITC presentations, and new patent filings
Strategic Developments: Manufacturing partnerships, leadership appointments, and regulatory pathway updates
Bookmark this page for direct access to Lyell's official press releases, SEC filings, and scientifically validated progress reports. Check regularly for updates on technologies addressing T-cell exhaustion and improving durable response rates in cancer immunotherapy.
Lyell Immunopharma (Nasdaq: LYEL) has initiated PiNACLE - H2H, a groundbreaking Phase 3 head-to-head CAR T-cell therapy trial comparing rondecabtagene autoleucel (ronde-cel) against approved CD19 CAR T-cell therapies for large B-cell lymphoma (LBCL) in second-line treatment.
Ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy with FDA's RMAT and Fast Track designations, is designed to improve complete response rates and durability. The trial will enroll approximately 400 patients starting early 2026, with event-free survival as the primary endpoint.
The company has formed a distinguished Steering Committee of lymphoma experts and is simultaneously advancing a single-arm pivotal trial (PiNACLE) for third-line-plus LBCL treatment, targeting approximately 120 patients.
Lyell Immunopharma (Nasdaq: LYEL), a late-stage clinical company focused on next-generation CAR T-cell therapies for cancer treatment, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th at 9:15 AM ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 10th at 8:00 AM ET. Investors can access the live webcasts through Lyell's website, with replays available after the presentations.
Lyell Immunopharma (Nasdaq: LYEL) reported significant progress in Q2 2025, highlighted by positive clinical data for their lead program LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma. The Phase 1/2 trial showed impressive results with an 88% overall response rate and 72% complete response rate in 3L+ patients.
The company has initiated the PiNACLE pivotal trial for third-line or later treatment and plans to begin a second-line trial by early 2026. Additionally, Lyell secured a $100 million private placement, with an initial closing of $50 million. The company's pro-forma cash position of $347 million is expected to fund operations through mid-2027.
Q2 2025 financial results showed a net loss of $42.7 million, an improvement from $45.8 million in Q2 2024, with R&D expenses decreasing to $34.9 million from $40.3 million year-over-year.
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage CAR T-cell therapy company, has secured a private placement agreement worth up to $100 million with institutional and accredited investors. The deal includes an initial $50 million closing at $13.32 per share, expected on July 25, 2025, with potential for an additional $50 million tied to clinical milestones.
The financing includes flexible terms with milestone-based pricing ranging from $10.41 to $25.61 per share and investor call options at $30.73 per share. The proceeds will fund two pivotal-stage trials of LYL314, including the PiNACLE trial for large B-cell lymphoma, and extend the company's cash runway into mid-2027.
Lyell Immunopharma (Nasdaq: LYEL) announced its participation in the H.C. Wainwright "HCW@Home" Series on June 25, 2025. The virtual fireside chat will feature CEO Lynn Seely and CFO Charlie Newton discussing their lead product LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma (LBCL).
The presentation will highlight recent positive clinical data presented at ICML and focus on next-generation CAR T-cell therapies. LYL314, which has received both RMAT and Fast Track designations from the FDA, aims to improve complete response rates and response duration compared to existing CD19-targeted therapies.